

## PRESS RELEASE

Stockholm February 16, 2023

### **ADDvise receives allocation decision worth approximately SEK 48 million**

ADDvise Group AB (publ)'s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Västra Götaland worth approximately SEK 48 million. The allocation decision consists of delivery of equipment for blood- and urine specimen collection during a four-year period starting May 2023.

The allocation decision can be appealed up until February 25, 2023.

#### **For further information, please contact:**

Rikard Akhtarzand, CEO  
+46 765-25 90 71  
rikard.akhtarzand@addvisigroup.se

#### **Important information:**

*This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on February 16, 2023 at 16:50 CET.*

#### **About ADDvise Group**

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at [www.addvisigroup.com](http://www.addvisigroup.com).